Participant AFE4 highlights yet another challenge of precision medicine wherein an actionable DNA-based feature is identified and targeted (that is, HER2 amplification), yet the tumor eventually evades the treatment by deleting the therapeutic target. This evidence concerns the gene ERBB2 and neoplasm.